Risperdal lawsuit documents could be sealed
Important Risperdal lawsuit 
documents could be sealed if the manufacturer of the drug has its way with the Philadelphia County Court of Common Pleas.
documents could be sealed if the manufacturer of the drug has its way with the Philadelphia County Court of Common Pleas.
One of Johnson & Johnson’s latest moves in the company’s ongoing fight to defend its research and promotion of Risperdal is to hide its research and promotion. The company is claiming – in the Philadelphia County Court of Common Pleas where 275 Risperdal cases now sit ready for trial – that it has proprietary rights which allow it to keep its Risperdal research sealed from the public. Because this information concerns the very same public targeted by J & J to use Risperdal, this argument seems of dubious merit at best.
Johnson & Johnson has already paid billions of dollars to settle federal and state allegations that it illegally marketed its drug Risperdal. More than 420 lawsuits have been filed in state courts against Johnson & Johnson over Risperdal. The suits allege that the drug stimulates breast growth and milk production in boys and young men.
Johnson & Johnson’s response to the lawsuits, claiming it has the right to keep the research behind Risperdal from the public and from plaintiffs’ lawyers, comes from a company statement which says, the research “materials are generated for scientists, researchers and regulatory authorities – not the general public. Simply stated, no legitimate purpose would be served by declassifying the documents identified by plaintiffs.”
Lawyers for plaintiffs, meanwhile, have argued to the court that the documents J & J seeks to hide are too vital to the public interest not to be released to the public, “and the data and materials being hidden by Janssen (a division of J & J) outweighs defendants’ claims to secrecy.’ The lawyers argue they cannot be hidden as they are safety documents requiring full disclosure for the well being of the public, as well as “full and unfettered review by regulatory authorities and the education of healthcare providers who are prescribing this powerful drug.”
Plaintiffs further argue that Risperdal’s maker has repeatedly misrepresented the drug’s safety to regulatory authorities, healthcare providers and the public. “Janssen systematically under-reported or misrepresented clinically important study results” relating to the chances of children and adolescents developing gynecomastia from Risperdal. However, says plaintiffs’ lawyers, this misrepresentation is currently “protected behind the shield of the protective order entered in this case.”
A hearing was held on Dec. 16, but so far no decision has been made on the matter.
Contact a Risperdal Lawyer Today
Risperdal lawsuit documents could be sealed
January 6, 2014 # 7:58 pm # Pharmaceutical Watch # No Comment
Important Risperdal lawsuit documents could be sealed if the manufacturer of the drug has its way with the Philadelphia County Court of Common Pleas.
documents could be sealed if the manufacturer of the drug has its way with the Philadelphia County Court of Common Pleas.
One of Johnson & Johnson’s latest moves in the company’s ongoing fight to defend its research and promotion of Risperdal is to hide its research and promotion. The company is claiming – in the Philadelphia County Court of Common Pleas where 275 Risperdal cases now sit ready for trial – that it has proprietary rights which allow it to keep its Risperdal research sealed from the public. Because this information concerns the very same public targeted by J & J to use Risperdal, this argument seems of dubious merit at best.
Johnson & Johnson has already paid billions of dollars to settle federal and state allegations that it illegally marketed its drug Risperdal. More than 420 lawsuits have been filed in state courts against Johnson & Johnson over Risperdal. The suits allege that the drug stimulates breast growth and milk production in boys and young men.
Johnson & Johnson’s response to the lawsuits, claiming it has the right to keep the research behind Risperdal from the public and from plaintiffs’ lawyers, comes from a company statement which says, the research “materials are generated for scientists, researchers and regulatory authorities – not the general public. Simply stated, no legitimate purpose would be served by declassifying the documents identified by plaintiffs.”
Lawyers for plaintiffs, meanwhile, have argued to the court that the documents J & J seeks to hide are too vital to the public interest not to be released to the public, “and the data and materials being hidden by Janssen (a division of J & J) outweighs defendants’ claims to secrecy.’ The lawyers argue they cannot be hidden as they are safety documents requiring full disclosure for the well being of the public, as well as “full and unfettered review by regulatory authorities and the education of healthcare providers who are prescribing this powerful drug.”
Plaintiffs further argue that Risperdal’s maker has repeatedly misrepresented the drug’s safety to regulatory authorities, healthcare providers and the public. “Janssen systematically under-reported or misrepresented clinically important study results” relating to the chances of children and adolescents developing gynecomastia from Risperdal. However, says plaintiffs’ lawyers, this misrepresentation is currently “protected behind the shield of the protective order entered in this case.”
A hearing was held on Dec. 16, but so far no decision has been made on the matter.
Contact a Risperdal Lawyer Today
If you have been injured by a Risperdal schedule your free initial consultation online or call us at 508-499-3366
Nice.RISPERDAL® CONSTA® (risperidone) is approved for the treatment of schizophrenia and for the maintenance treatment of Bipolar I Disorder. Risperdal risperal lawsuit
ReplyDelete